Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AF Ablation Procedures Driving CRM Market Expansion

Executive Summary

Cardiac rhythm management device sales in the US are projected to grow at a compound annual rate of 2.9%, increasing to an estimated $8.2 billion in the year 2019. Two of the fastest growing sectors of the market, electrophysiology and ablation devices, will be driven by a 10% to 20% growth in the number of patients treated for atrial fibrillation.

You may also be interested in...



Acutus Is Trying To Fundamentally Change Understanding Of Arrhythmia With AcQMap

New trial results show Acutus Medical's AcQMap platform has the ability to classify conduction patterns and localized non-pulmonary-vein therapeutic targets for ablation to treat atrial fibrillation, which could have implications for both treatment of atrial fibrillation and understanding the genetic markers for this common arrhythmia, according to the authors.

New Approaches To AF Ablation And Mapping

The market for atrial fibrillation catheter ablation devices continues to grow even as the field wrestles with basic questions and as new study results may dampen enthusiasm for some technologies. Though strategics dominate this sector, innovators with new approaches to ablation and mapping hope to help resolve unknowns and take a piece of this vast and underpenetrated market.

SJM’s Endosense Deal Highlights Growing Importance Of Contact Force Technology In AF Ablation

St. Jude Medical has acquired Swiss company Endosense, a pioneer in the field of contact force sensing for atrial fibrillation ablation. The $170 million plus milestones deal will enable St. Jude to compete more effectively against market leader Biosense Webster/J&J, but it also emphasizes the growing importance of contact force technology in the AF ablation space.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035878

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel